Your session is about to expire
← Back to Search
CBD for Chronic Low Back Pain (CBD Trial)
CBD Trial Summary
This trial will study whether CBD, a non-intoxicating compound found in cannabis, can help relieve chronic low back pain and depression.
CBD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCBD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 2 trial • 50 Patients • NCT01844687CBD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do you accept individuals over 18 years of age in this trial?
"Candidates for this trial must be within the age bracket of 18 to 75 years old."
How many participants are being recruited to this clinical research endeavor?
"Affirmative. According to clinicaltrials.gov, this experiment began recruitment on April 1st 2022 and is still currently seeking interested participants. This project necessitates 80 volunteers from a single site."
Are there any additional studies which have explored the properties of CBD?
"Currently, 79 studies are assessing the effects of CBD with 16 in Phase 3. There is a concentration of these trials located in Ribeirao Preto and Sao Paulo; however, there are 290 total sites hosting clinical research regarding cannabidiol."
Is it possible for me to enroll in this trial?
"For this clinical study, 80 participants of ages 18 to 75 with back pain must be identified."
Are there any vacancies for the trial that are still unoccupied?
"According to the clinicaltrials.gov database, this medical research is currently accepting participants. The trial was initially announced on April 1st 2022 and its details were last modified on August 25th of the same year."
Has the FDA granted its authorization for CBD?
"As this Phase 2 trial does not yet have efficacy data, the safety of CBD was judged to be a score of two."
What is the ultimate aim of this research endeavor?
"This clinical study is primarily evaluating the degree of Transformation in Thalamus Neuroinflammation from Initial Measurement to Week 4. Secondary outcomes include Assessing Alterations in Depression-linked Neuroinflammation through [11C]PBR28 PET scans located in Limbic Regions (pgACC, aMCC), Adjustments in Pain Intensity as measured by the Brief Pain Inventory - Short Form's "Worst Pain" Item ranging from 0–10 and Modifications in Depressive Symptoms tracked with Beck Depression Inventory-II Scores between 0–63."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger